bluebird bio | Setting the standard for gene therapy
For more than a decade, we’ve forged new paths for gene therapies and are improving and advancing at every step. We have the largest and deepest ex-vivo gene therapy data set in the world—driving the field forward, but we aren’t doing this alone. We learn from the realities of …
Biologic and Clinical Efficacy of LentiGlobin for Sickle Cell Disease
Dec 12, 2021 · Gene therapy with LentiGlobin for sickle cell disease (bb1111; lovotibeglogene autotemcel, Bluebird Bio) consists of the autologous transplantation of hematopoietic stem and progenitor cells ...
bluebird bio - Wikipedia
bluebird bio, Inc., based in Somerville, Massachusetts, is a biotechnology company that develops gene therapies for severe genetic disorders. [ 1 ] The company's only - in the European Union (EU) - approved drug is betibeglogene autotemcel (Zynteglo), which treats transfusion-dependent beta thalassemia (TDT), a rare genetic blood disorder, and ...
LYFGENIA™ (lovotibeglogene autotemcel) | An FDA Approved …
If you are diagnosed with a cancer, have your treating physician contact bluebird bio at 1-833-999-6378. You may experience side effects associated with other medicines, including a chemotherapy medicine, administered as part of the LYFGENIA treatment regimen.
bluebird bio | our research
View the bluebird bio development pipeline and explore our list of gene therapy products and candidates at all development phases.
About Us - bluebird bio
bluebird bio is pioneering gene therapy with purpose. We’re putting our care and expertise to work across a spectrum of rare disorders and cancers.
bluebird bio Announces FDA Approval of LYFGENIA™ …
Dec 8, 2023 · Clinical Data Supporting Approval of LYFGENIA The FDA approval of LYFGENIA builds on decades of research into lentiviral vector gene addition therapy and the largest clinical development program of any gene therapy for sickle cell disease. The label is based on data from patients from the Phase 1/2 HGB-206 study.
Cancer cases in bluebird’s gene therapy trials - Nature
3 days ago · Over 10% of patients with a fatal neurodegenerative disease who received bluebird bio’s FDA-approved gene therapy Skysona (elivaldogene autotemcel) have developed hematological cancers, further ...
Lentiviral vector gene therapies come of age with two FDA approvals
Oct 14, 2022 · Bluebird bio has now secured FDA approvals for two lentiviral vector gene therapies for rare diseases. Melissa Bonner, the company’s head of research, discusses the rocky road to success and ...
Press Release - bluebird bio, Inc.
SOMERVILLE, Mass.--(BUSINESS WIRE)--Dec. 9, 2023-- bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or “bluebird”) today announced new and updated efficacy, safety and health-related quality of life (HRQoL) data from the Phase 1/2 HGB-206 Group C and Phase 3 HGB-210 studies of lovotibeglogene autotemcel (lovo-cel) gene therapy for ...